...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States
【24h】

Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States

机译：美国轮状病毒疫苗系列的完成情况和在接受管理的婴儿中遵守疫苗接种时间表的情况

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Two rotavirus vaccines are currently approved in the United States: 3-dose RotaTeq (RV5; Merck & Co., Inc., Whitehouse Station, NJ, USA) is administered at ages 2, 4, and 6 months; and 2-dose Rotarix (RV1; GlaxoSmithKline, Research Triangle Park, NC, USA) is administered at ages 2 and 4 months. Our objective was to compare rotavirus vaccine series completion and dosing schedule compliance between cohorts of infants who received these vaccines. Methods: Infants aged less than 1 year who initiated a rotavirus vaccine series between 01 January 2009 and 30 June 2009 were identified in US health insurance claims data. Cohorts were formed based on vaccine brand use. Series completion and compliance with the FDA-approved and ACIP-recommended harmonized schedules were analyzed descriptively and a log binomial model was used to estimate the difference in series completion by vaccine brand while adjusting for demographic variables. Results: Among infants in the RV1 and RV5 cohorts (N=55,584), 84.3% completed a full series. A greater proportion of the RV1 cohort than the RV5 cohort completed their series (91.0% vs. 83.4%; P < 0.001; multivariate-adjusted relative risk 1.07; 95% CI 1.06-1.08). In the RV1 and RV5 cohorts, respectively, 75.0% and 59.5% of infants were fully compliant with the FDA-approved administration schedule for their vaccine (P < 0.001); 83.3% and 76.4% of infants were fully compliant with the harmonized schedule (P < 0.001). Conclusions: The proportion of infants that completed the series was greater and compliance with respective FDA-approved and harmonized dosing schedules was higher among infants vaccinated with RV1 than among infants who received RV5. (C) 2011 Elsevier Ltd. All rights reserved.
机译：背景：美国目前已批准了两种轮状病毒疫苗：3剂量的RotaTeq（RV5;默克公司，美国新泽西州怀特豪斯站）分别在2、4和6个月大时使用; 2个月和4个月大时服用2剂量Rotarix（RV1;葛兰素史克（GlaxoSmithKline），美国北卡罗来纳州研究三角公园）。我们的目的是比较轮状病毒疫苗系列的完成情况和接受这些疫苗的婴儿队列之间的服药时间表。方法：从美国健康保险索赔数据中识别出2009年1月1日至2009年6月30日期间开始接种轮状病毒疫苗系列的1岁以下婴儿。根据疫苗品牌使用组建了队列。描述性地分析了系列完成度和是否符合FDA批准和ACIP推荐的协调时间表，并使用对数二项式模型估算了疫苗品牌在系列完成度方面的差异，同时调整了人口统计学变量。结果：在RV1和RV5队列中的婴儿（N = 55,584）中，有84.3％完成了整个系列。 RV1队列的比例高于RV5队列的比例（91.0％比83.4％; P <0.001;多元校正相对风险1.07; 95％CI 1.06-1.08）。在RV1和RV5队列中，分别有75.0％和59.5％的婴儿完全符合FDA批准的疫苗接种时间表（P <0.001）; 83.3％和76.4％的婴儿完全符合统一的时间表（P <0.001）。结论：接种RV1的婴儿比完成RV5的婴儿完成该系列婴儿的比例更高，并且符合FDA批准的相应剂量表的一致性更高。 （C）2011 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号